Synopsis: Healthcare stock surged 12 percent after FY26 results, driven by strong biotech growth, emerging market expansion, margin improvement, and a turnaround in profitability to Rs 199 crore PAT. The share of this company, which focuses on pharmaceutical...
Synopsis: Wockhardt’s remarkable turnaround, rising over 861 percent after a decade-long 93 percent decline, is driven by breakthrough antibiotic Zaynich, a strong biotech portfolio, global approvals, and margin recovery, showing how innovation and execution can...
